WNT5A and melanoma: In contrast to its activity in melanoma, Wnt5a shows tumor-suppressing activity in the breast, and restoring this protein can suppress migration of breast cancer cells – activity recapitulated by a formylated hexapeptide Foxy-5 also derived from Wnt5a[52, 53]; this drug candidate is currently in phase I clinical trials.